ARTICLE | Clinical News
TRV027: Phase IIb ongoing
March 16, 2015 7:00 AM UTC
A DSMB recommended continuation of the double-blind Phase IIb BLAST-AHF trial comparing 1, 5 and 25 mg/hour IV TRV027 given continuously for 48-96 hours plus standard therapy vs. placebo plus standard...